Pfizer PFE-2.06%decrease; red down pointing triangle has sold 700 million shares in British consumer-healthcare business Haleon HLN-0.11%decrease; red down pointing triangle for 2.50 billion ...
(Reuters) -Pfizer is looking to sell about 700 million ordinary shares in Haleon, its bookrunner J.P. Morgan said on Tuesday, lowering its stake in the British consumer healthcare company to about ...
Pfizer (NYSE:PFE) announced Tuesday it plans to sell roughly 700M ordinary shares in Haleon (NYSE:HLN) to lower its stake in the British consumer healthcare giant from about 15.0% to 7.3% ...
Once complete, Pfizer's stake in Haleon will fall from 15.0% to around 7.3%. Pfizer's move comes after Haleon's spin-off as an independent consumer healthcare company, part of plans to reshape its ...
(Bloomberg) -- Pfizer Inc. sold about 700 million shares in Haleon Plc, further paring its stake in the maker of Sensodyne toothpaste. The deal raised around £2.5 billion ($3.1 billion ...
Shares of Haleon plc (NYSE:HLN – Get Free Report) have been assigned a consensus recommendation of “Moderate Buy” from the ...
Pfizer (PFE) announces that it intends to sell approximately 700M ordinary shares in Haleon plc (HLN), representing approximately 7.7% of Haleon’s issued share capital. “There will be no sale ...
Pfizer plans to cut its stake in Haleon through an accelerated bookbuilding process to institutional investor, starting immediately. The New York drugmaker said Tuesday that the proposed sale ...
(RTTNews) - Pfizer Inc. (PFE) Wednesday announced the sale of 700 million shares in Haleon Plc (HLN), a British multinational consumer healthcare company, at 357 pence per share or approximately $ ...
In an interview with Gulf Business, Charles Leslie, global business lead for the Pain Portfolio & Systemics at Haleon ... how we view health and wellness. One of the most noticeable trends ...
Pfizer has sold 700 million shares in British consumer-healthcare business Haleon for 2.50 billion pounds, equivalent to US$3.05 billion, it said in a statement. The U.S. drugmaker said Wednesday ...